<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00853957</url>
  </required_header>
  <id_info>
    <org_study_id>CSPA100AUS01</org_study_id>
    <nct_id>NCT00853957</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension</brief_title>
  <acronym>AACESS</acronym>
  <official_title>An 8-week Multicenter, Randomized, Double-blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine (150/5 mg, 300/10 mg) Versus Amlodipine Alone (5 mg, 10 mg) in African American Patients With Stage 2 Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the BP-lowering efficacy of the combination of
      aliskiren and amlodipine, as initial therapy, compared to amlodipine monotherapy in African
      American patients with Stage II hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>To compare the change from baseline in mean sitting systolic blood pressure (msSBP) after 8 weeks of treatment with a combination of aliskiren and amlodipine treatment regimen (150/5 mg, 300/10 mg) versus an amlodipine treatment regimen (5 mg, 10 mg) in African American patients with Stage 2 hypertension.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>To compare the change from baseline in mean sitting diastolic blood pressure (msDBP) after 8 weeks of treatment with a combination of aliskiren and amlodipine treatment regimen (150/5 mg, 300/10 mg) versus an amlodipine treatment regimen (5 mg, 10 mg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Blood Pressure (BP) Control (&lt;140/90 mmHg)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Cumulative percentage of patients achieving BP control (&lt;140/90 mmHg)for both treatment arms was calculated. Cumulative refers to achieving blood pressure control before or at the corresponding visit. If achieving blood pressure control occurred more than once, only the first occurrence was counted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders (Patients With MSSBP &lt; 140 mmHg or Decrease From Baseline of Greater Than or Equal to 20 mmHg)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Cumulative percentage of responders (Responders are defined as patients with MSSBP &lt;140 mmHg or a decrease from baseline ≥20 mmHg) during 8 weeks of treatment was calculated. Cumulative refers to achieving blood pressure control before or at the corresponding visit. If achieving blood pressure control occurred more than once, only the first occurrence was counted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in MSSBP at Week 1 and 4</measure>
    <time_frame>Baseline, 1 and 4 weeks</time_frame>
    <description>Compare the change from baseline in MSSBP at week 1 and 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Peripheral Edema by Visit</measure>
    <time_frame>8 weeks</time_frame>
    <description>Cumulative percentage of patients with peripheral edema was calculated. 'Cumulative' refers to patients with peripheral edema before or at the corresponding visit. If peripheral edema occurred more than once, only the first occurrence was counted. Peripheral edema is the swelling of tissues due to the accumulation of fluids. Peripheral edema was assessed by investigators during physical examination.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">443</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Aliskiren/Amlodipine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amlodipine 5mg titrated to 10 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren/Amlodipine</intervention_name>
    <description>Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg</description>
    <arm_group_label>Aliskiren/Amlodipine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>Amlodipine 5 mg titrated to 10mg</description>
    <arm_group_label>Amlodipine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women of African American background; self identified

          -  Patients with stage 2 hypertension defined as MSSBP ≥ 160 mmHg and &lt; 200 mmHg at Visit
             5 (randomization

        Exclusion Criteria:

          -  Office blood pressure measured by cuff (MSDBP ≥ 110 mmHg and/or MSSBP ≥ 200 mmHg)

          -  Patients on 4 or more antihypertensive medications.

          -  Patients with uncontrolled hypertension (MSSBP &gt;180 mmHg) taking more than 1
             antihypertensive medication at Visit 1

          -  Refractory hypertension, defined as, unresponsive to triple drug therapy at the
             maximum dose of each drug, one of which must be a diuretic, and not at blood pressure
             goal (140/90 mmHg). Therapy with a fixed dose combination of two active substances
             represent two drugs.

          -  History of malignancy of any organ system (other than localized basal cell carcinoma
             of the skin), treated or untreated, within the past 5 years, regardless of whether
             there is evidence of local recurrence or metastases.

          -  Evidence of a secondary form of hypertension, including but not limited to any of the
             following:

               -  coarctation of the aorta

               -  hyperaldosteronism

               -  unilateral or bilateral renal artery stenosis

               -  Cushing's disease

               -  polycystic kidney disease

               -  pheochromocytoma

          -  Known Keith-Wagener grade III or IV hypertensive retinopathy.

          -  History of angioedema due to usage of an ARB or ACE inhibitor.

          -  History of hypertensive encephalopathy, cerebrovascular accident, transient ischemic
             attack, heart failure (NYHA Class II-IV), coronary bypass graft surgery (CABG),
             percutaneous coronary intervention (PCI), unstable angina pectoris, or myocardial
             infarction in the last 12 months

        Other protocol defined inclusion/exclusion criteria applied
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Oxon Hill</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Trenton</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Springfield Gardens</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Milwaukeee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2009</study_first_submitted>
  <study_first_submitted_qc>February 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2009</study_first_posted>
  <results_first_submitted>December 6, 2010</results_first_submitted>
  <results_first_submitted_qc>December 22, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 21, 2011</results_first_posted>
  <last_update_submitted>April 26, 2012</last_update_submitted>
  <last_update_submitted_qc>April 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>African Americans</keyword>
  <keyword>Aliskiren</keyword>
  <keyword>Amlodipine</keyword>
  <keyword>Systolic blood pressure</keyword>
  <keyword>Diastolic blood pressure</keyword>
  <keyword>Stage II</keyword>
  <keyword>Combination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aliskiren/Amlodipine</title>
          <description>Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg</description>
        </group>
        <group group_id="P2">
          <title>Amlodipine</title>
          <description>Amlodipine 5mg titrated to 10 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="220"/>
                <participants group_id="P2" count="223"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="206"/>
                <participants group_id="P2" count="204"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aliskiren/Amlodipine</title>
          <description>Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg</description>
        </group>
        <group group_id="B2">
          <title>Amlodipine</title>
          <description>Amlodipine 5mg titrated to 10 mg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="220"/>
            <count group_id="B2" value="223"/>
            <count group_id="B3" value="443"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.2" spread="9.33"/>
                    <measurement group_id="B2" value="52.4" spread="10.57"/>
                    <measurement group_id="B3" value="52.8" spread="9.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;55 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥55 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)</title>
        <description>To compare the change from baseline in mean sitting systolic blood pressure (msSBP) after 8 weeks of treatment with a combination of aliskiren and amlodipine treatment regimen (150/5 mg, 300/10 mg) versus an amlodipine treatment regimen (5 mg, 10 mg) in African American patients with Stage 2 hypertension.</description>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>Full analysis set, Last Observation Carried Forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren/Amlodipine</title>
            <description>Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine</title>
            <description>Amlodipine 5mg titrated to 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)</title>
          <description>To compare the change from baseline in mean sitting systolic blood pressure (msSBP) after 8 weeks of treatment with a combination of aliskiren and amlodipine treatment regimen (150/5 mg, 300/10 mg) versus an amlodipine treatment regimen (5 mg, 10 mg) in African American patients with Stage 2 hypertension.</description>
          <population>Full analysis set, Last Observation Carried Forward (LOCF)</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.1" spread="14.53"/>
                    <measurement group_id="O2" value="-27.8" spread="13.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)</title>
        <description>To compare the change from baseline in mean sitting diastolic blood pressure (msDBP) after 8 weeks of treatment with a combination of aliskiren and amlodipine treatment regimen (150/5 mg, 300/10 mg) versus an amlodipine treatment regimen (5 mg, 10 mg).</description>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>Full analysis set, Last Observation Carried Forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren/Amlodipine</title>
            <description>Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine</title>
            <description>Amlodipine 5mg titrated to 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)</title>
          <description>To compare the change from baseline in mean sitting diastolic blood pressure (msDBP) after 8 weeks of treatment with a combination of aliskiren and amlodipine treatment regimen (150/5 mg, 300/10 mg) versus an amlodipine treatment regimen (5 mg, 10 mg).</description>
          <population>Full analysis set, Last Observation Carried Forward (LOCF)</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.7" spread="9.60"/>
                    <measurement group_id="O2" value="-10.4" spread="9.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving Blood Pressure (BP) Control (&lt;140/90 mmHg)</title>
        <description>Cumulative percentage of patients achieving BP control (&lt;140/90 mmHg)for both treatment arms was calculated. Cumulative refers to achieving blood pressure control before or at the corresponding visit. If achieving blood pressure control occurred more than once, only the first occurrence was counted.</description>
        <time_frame>8 weeks</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren/Amlodipine</title>
            <description>Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine</title>
            <description>Amlodipine 5mg titrated to 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving Blood Pressure (BP) Control (&lt;140/90 mmHg)</title>
          <description>Cumulative percentage of patients achieving BP control (&lt;140/90 mmHg)for both treatment arms was calculated. Cumulative refers to achieving blood pressure control before or at the corresponding visit. If achieving blood pressure control occurred more than once, only the first occurrence was counted.</description>
          <population>Full analysis set</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4"/>
                    <measurement group_id="O2" value="57.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Responders (Patients With MSSBP &lt; 140 mmHg or Decrease From Baseline of Greater Than or Equal to 20 mmHg)</title>
        <description>Cumulative percentage of responders (Responders are defined as patients with MSSBP &lt;140 mmHg or a decrease from baseline ≥20 mmHg) during 8 weeks of treatment was calculated. Cumulative refers to achieving blood pressure control before or at the corresponding visit. If achieving blood pressure control occurred more than once, only the first occurrence was counted.</description>
        <time_frame>8 weeks</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren/Amlodipine</title>
            <description>Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine</title>
            <description>Amlodipine 5mg titrated to 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders (Patients With MSSBP &lt; 140 mmHg or Decrease From Baseline of Greater Than or Equal to 20 mmHg)</title>
          <description>Cumulative percentage of responders (Responders are defined as patients with MSSBP &lt;140 mmHg or a decrease from baseline ≥20 mmHg) during 8 weeks of treatment was calculated. Cumulative refers to achieving blood pressure control before or at the corresponding visit. If achieving blood pressure control occurred more than once, only the first occurrence was counted.</description>
          <population>Full analysis set</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3"/>
                    <measurement group_id="O2" value="86.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in MSSBP at Week 1 and 4</title>
        <description>Compare the change from baseline in MSSBP at week 1 and 4</description>
        <time_frame>Baseline, 1 and 4 weeks</time_frame>
        <population>Full analysis set, Last Observation Carried Forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren/Amlodipine</title>
            <description>Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine</title>
            <description>Amlodipine 5mg titrated to 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in MSSBP at Week 1 and 4</title>
          <description>Compare the change from baseline in MSSBP at week 1 and 4</description>
          <population>Full analysis set, Last Observation Carried Forward (LOCF)</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.5" spread="12.53"/>
                    <measurement group_id="O2" value="-18.2" spread="13.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline to Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.9" spread="13.30"/>
                    <measurement group_id="O2" value="-27.3" spread="13.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Peripheral Edema by Visit</title>
        <description>Cumulative percentage of patients with peripheral edema was calculated. 'Cumulative' refers to patients with peripheral edema before or at the corresponding visit. If peripheral edema occurred more than once, only the first occurrence was counted. Peripheral edema is the swelling of tissues due to the accumulation of fluids. Peripheral edema was assessed by investigators during physical examination.</description>
        <time_frame>8 weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren/Amlodipine</title>
            <description>Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine</title>
            <description>Amlodipine 5mg titrated to 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Peripheral Edema by Visit</title>
          <description>Cumulative percentage of patients with peripheral edema was calculated. 'Cumulative' refers to patients with peripheral edema before or at the corresponding visit. If peripheral edema occurred more than once, only the first occurrence was counted. Peripheral edema is the swelling of tissues due to the accumulation of fluids. Peripheral edema was assessed by investigators during physical examination.</description>
          <population>Full Analysis Set</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                    <measurement group_id="O2" value="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8"/>
                    <measurement group_id="O2" value="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aliskiren/Amlodipine</title>
          <description>Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg</description>
        </group>
        <group group_id="E2">
          <title>Amlodipine</title>
          <description>Amlodipine 5mg titrated to 10 mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

